InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $163.58M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 3.05M
Average 1.80M
IFRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
InflaRx N.V.NASDAQ: IFRX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of €7.52M (cash outflow) fell 46.4% year over year, behind the -39.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 59.8% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Free cash flow amounted to 116026.4% of revenue in FY2025, up 86709.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -46.4% toward the trailing-twelve-month pace of -39.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (34.03M) EUR
- Year-over-year change
- +30.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.03M) | +30.0% |
| FY2024 | 2024-12-31 | (48.6M) | -28.3% |
| FY2023 | 2023-12-31 | (37.89M) | -11.8% |
| FY2022 | 2022-12-31 | (33.91M) | +15.2% |
| FY2021 | 2021-12-31 | (39.97M) | — |
Free Cash Flow vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.4% is the lowest of 8, against a peer median of +31.6%.
- Free cash flow amounts to 98624.1% of revenue for IFRX, versus a peer median of 17668.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.14M USD | -23.4% | +246.3% | 152.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $80.18M USD | +31.6% | +11.6% | — |
| LTM Mar 2026 | $59.3M USD | -4.7% | +12.6% | 31209.5% | |
IMAImageneBio Inc | LTM Mar 2026 | $52.08M USD | +36.1% | -14.1% | — |
| FY2025 | $51.64M USD | +112.0% | -20.7% | 80687.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $49.09M USD | — | +64.1% | — |
| LTM Mar 2026 | $41.28M USD | -26.9% | -27.8% | 4128.2% | |
| LTM Mar 2026 | $32.82M USD | +115.0% | +23.3% | — | |
| LTM Mar 2026 | €28.93M EUR | -39.4% | +0.1% | 98624.1% | |
| Peer median (excluding IFRX) | — | +31.6% | +12.1% | 17668.8% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (43.83M) |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 402.93K |
| Deferred Income Tax | 1.16M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.33M | 6.04M | 3.41M | 4.07M | 0 |
| Change in Working Capital | 1.54M | (9.77M) | 1M | (2.28M) | 4.66M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 2.12M |
| Inventory | 0 | 0 | (11.37M) | 4.47M | 6.63M |
| Accounts Payables | 316.11K | (3.52M) | 0 | 0 | (5.76M) |
| Other Working Capital | 1.22M | (6.25M) | 12.37M | (6.75M) | 1.68M |
| Other Non-Cash Items | (2M) | (1.13M) | (131.29K) | (4.76M) | 4.84M |
| Operating Cash Flow | (39.94M) | (33.74M) | (37.81M) | (48.56M) | (33.92M) |
| Capital Expenditures | (37.78K) | (162.39K) | (81.1K) | (46.87K) | (111.13K) |
| Acquisitions (Net) | 37.78K | (19.52M) | 0 | 0 | 0 |
| Purchases of Investments | (97.52M) | (64.47M) | (104.05M) | (35.34M) | (44.28M) |
| Sales of Investments | 71.6M | 84M | 86.44M | 87.75M | 47.5M |
| Other Investing Activities | (37.78K) | 19.52M | 0 | 1 | (3) |
| Investing Cash Flow | (25.95M) | 19.36M | (17.7M) | 52.36M | 3.11M |
| Debt Repayment | (360.64K) | (364.43K) | (373.98K) | (388.11K) | (357.58K) |
| Common Stock Issued | 65.14M | 2.35M | 56.48M | 1.1M | 32.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.2M) | (47.74K) | (3.12M) | (323.73K) | 14.11K |
| Financing Cash Flow | 61.58M | 1.94M | 52.99M | 386.45K | 32M |
| Effect of Forex Changes | 4.59M | 2.46M | (974.1K) | 1.41M | (1.37M) |
| Net Change in Cash | 281.31K | (9.98M) | (3.5M) | 5.61M | (179.66K) |
| Free Cash Flow | (39.97M) | (33.91M) | (37.89M) | (48.6M) | (34.03M) |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.